Vir Biotechnology shares are trading higher after HC Wainwright maintained a Buy rating on the stock and raised its price target from $85 to $110.
Portfolio Pulse from Benzinga Newsdesk
Vir Biotechnology's stock price increased following HC Wainwright's decision to maintain a Buy rating and raise its price target from $85 to $110.
February 14, 2024 | 4:20 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
HC Wainwright maintained a Buy rating on Vir Biotechnology and increased the price target from $85 to $110, leading to a rise in the stock price.
The upgrade in the price target by a reputable financial institution like HC Wainwright can significantly influence investor sentiment and stock price. Given the substantial increase from $85 to $110, this reflects a strong conviction in the company's future performance and potential, likely leading to increased investor interest and a short-term rise in stock price.
CONFIDENCE 95
IMPORTANCE 90
RELEVANCE 100